CERT (Certara) Valuation Rank


CERT Certara Inc CERT
59 GF Score
Price $5.43
GF Value $13.40
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Certara Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Certara Valuation Rank Related Terms

CERT
59GF Score
Certara Inc CERT
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Certara (CERT) Overvalued in 2026?

Based on GuruFocus' analysis, Certara stock appears to be undervalued. The current stock price of $5.43 is trading 59.5% below its estimated GF Value™ of $13.40. GuruFocus considers Certara to be Possible Value Trap.

Key valuation signals for CERT:

  • Valuation Rank:
  • GF Value™: $13.40 vs. price of $5.43 (59.5% below fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the CERT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Certara Business Description

Address 4 Radnor Corporate Center, Suite 350, Radnor, PA, USA, 19087
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
59GF Score

Get the complete analysis for CERT

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.43
Price
$13.40
GF Value